The aim of this article is to highlight the evidence on new and ongoing vaccine safety concerns in the light of several vaccines recently licensed and others made available and recommended more widely.
Introduction
Immunization safety is a real concern because all vaccines may cause side effects. Both healthcare workers and patients need reminding that immunization is an induced, controlled stimulus to the immune system, so some adverse reactions can be expected. Most reactions, however, are transient and mild. Immunization safety concerns have existed since the day of the first available vaccine. Since the introduction of Jenner's cowpox vaccine, however, the benefits of saving children from tragic outcomes of common diseases outweighed the risks of perceived adverse events following immunization (AEFIs).
Immunization safety concerns are different from concerns about other medical interventions, because they are administered to generally healthy individuals and the tolerance of AEFIs is substantially lower compared to adverse events following medication for an existing illness. As successful vaccination programs span several generations over time, no doctor, nurse or parent may have ever seen the prevented diseases. It will be an increasing challenge to communicate the benefits of immunization in the apparent absence of disease and the presence of AEFIs, even if mild.
Also, safety concerns are increasing as the success of immunization systems increases. With a decreasing incidence of disease, public attention shifts towards AEFIs. It is then only a matter of time until a concern will be raised and publicized, public confidence might be lost, immunization rates will then decrease and a resurgence of disease is likely to follow. Therefore, maintaining the success of immunization programs critically relies on public confidence, which is based on public perception. Public perception depends on the quality of information provided. Information about the safety of immunizations needs to be placed on the most rigorous scientific basis possible, because concerns may lead to withdrawal of the product from the market, modification of the pertinent recommendations, or loss of public confidence.
Immunization safety concerns often follow a recognizable pattern: the alleged AEFI is a prevalent medical entity of increasing prevalence or unknown cause; the AEFI is suggested to be caused by immunization by some investigators; the methodology of the 'index study' (and subsequent studies by the same study group) is inadequate (typically poorly or not controlled case series); public communication is made prematurely, resonating with individuals suffering from the medical entity, but underestimating the potential of harming those who could be protected by the vaccine; the results of the 'index study' are not reproducible by other study groups; regaining public confidence is a slow process over several years.
The aim of this article is to highlight recent evidence on immunization safety concerns related to currently licensed vaccines.
Definition of term and concept
The lack of a common language and clear understanding of what AEFIs are is at the heart of generating and spreading myth. AEFIs are potentially harmful and unintended medical incidents taking place after immunization. Hence, they are temporally associated with, but not necessarily the result of, administration of a vaccine. Although a temporal association is a necessary condition, it is insufficient to establish a causal relation. Even a biologically plausible temporal association is not sufficient to assume a causal relation. In fact, assumed biological plausibility has often been misleading and thus provided a more sophisticated variant of the post hoc ergo propter hoc fallacy. The term 'adverse reaction' or 'side effect' should only be used if a causal relation between an AEFI and immunization has been established based on the appropriate Hill's criteria (e.g. consistency, strength of association, specificity, temporality, biological plausibility) [1,2]. Table 1 outlines typical AEFIs for which current scientific evidence does not support the hypothesis of a causal relation. Table 2 outlines typical AEFIs for which there is limited scientific evidence indicating a causal relation with immunization. Allocation to either group has not changed for any of the AEFIs during the last few years.
Adverse events following immunization

Atopic disease
Based on the 'hygiene hypothesis' some infectious diseases are claimed to protect from atopic disease, because microbial pressure leads to a reduction in Th2 responses in favor of Th1 responses [3 ,4 ] . The claim is that vaccines reduce microbial pressure and thus have contributed to the increasing incidence of atopic disease. This is probably not the case, however, because the driving force of microbial pressure in early life is colonization of the gastrointestinal tract, which is unchanged by immunization; in infancy and childhood, microbial pressure is driven by common organisms which are not (yet) widely prevented by vaccines (e.g., rotaviruses, influenza, rhinoviruses, adenoviruses, and enteroviruses); changes in the prevalence of atopic disease were not associated with changes in immunization schedules; potential IgE synthesis is vaccine-specific and does not expand to environmental antigens associated with atopic disease [5, 6] . A recent study on more than half a million children challenged the hygiene hypothesis and concluded that atopic constitution is associated with increased susceptibility to acute infections and protection by immunization might be particularly warranted [7 ] .
Recent data from an observational cohort study with secondary record linkage including 8443 Australian children underlines this evidence. This study has shown positive associations between diphtheria immunization and asthma [odds ratio (OR) 1.3, 95% confidence interval (CI) 1.1-1.7] and between diphtheria, tetanus, pertussis (DTP) and polio immunization and excema and food allergies with OR between 1.4 and 1.5 and 95% CI 238 Paediatric and neonatal infections An increased risk of asthma or reactive airway disease following live attenuated influenza vaccine (LAIV) was suggested for children aged 18-35 months, leading to the restricted licensure of the vaccine to children above 5 years [11] . Another recent large study, however, including 11 000 children (aged 18 months to 18 years) receiving almost 20 000 doses of vaccine during four seasons suggested the absence of an association comparing the pre-vaccination and post-vaccination periods [12] . Passive surveillance data on the first two seasons after licensure comprising administration of 2.5 million doses confirm the excellent safety profile of LAIV [13] .
Autism
An association between measles, mumps and rubella (MMR) immunization and inflammatory bowel disease and autism was claimed in the late 1990s [14, 15] . These studies were not scientifically stringent and had serious methodological limitations.
A recent Canadian study [16 ] added to the evidence against an association between pervasive developmental disorder (including autism) and the exposure to MMR. The same study failed to show an association between ethyl-mercury (thiomersal), a preservative in some vaccines, and neurobehavioural disorders. For three birth cohorts included in the study, autism was increasing with decreasing thiomersal exposure. The highest rates of pervasive developmental disorder were observed in children with no vaccine-related thiomersal exposure. This is in line with previous studies demonstrating that diagnosis of autism spectrum disease continued to increase while MMR uptake was decreased or discontinued [17] [18] [19] [20] .
Two independent studies in Canada and the United Kingdom involving a total of 69 children with autism spectrum disorder did not detect a single copy of the measles genome in peripheral blood leukocytes of cases and controls by highly sensitive PCR [21 ,22 ] . These studies also elegantly highlighted technical and meth-odological errors and flaws of previous studies and thus refuted the hypothesis that persistence of measles nucleic acid is associated with an increased risk of developing autism [23] [24] [25] .
Encephalopathy
Encephalopathy was an alleged AEFI, most prominently following whole cell pertussis and measles vaccine. A recent case-control study, however, including 452 cases (57 immunized) added to the evidence against a causal association. Odds ratios for any time window following immunization were smaller than 1.2 with wide confidence intervals spanning 1 and P values over 0.05 [26 ] . The background to another recent study is the increasing recognition of severe myoclonic epilepsy as an epileptic syndrome in infancy. It appears to be associated with mutations in the SCN1A gene, coding for a neuronal sodium channel subunit. This study has shown SCN1A mutations in 11 of 14 patients with encephalopathy following immunization, suggesting a genetically determined epileptic encephalopathy presenting coincidentally or triggered rather than caused by immunization [27 ] .
Multiple sclerosis
A causal association between multiple sclerosis (MS) and hepatitis B vaccine was suggested by several case reports during the French immunization campaign [28] . Increased reporting to the national surveillance system following publication of the first concern augmented public misconception. Many subsequent epidemiological studies showed no association. In 2004, a case-control study in the UK claimed evidence in support of an association [29] . This study, however, suffered from a number of methodological problems, undermining the validity of the conclusions. The attempt to reproduce these results failed in a larger study using a large linked database in the US [30] [31] [32] . In 2006, Hernan and Jick [33] concurred that there is no conclusive evidence for a causal relation to date.
Piaggio et al. [34] investigated T-cell responses to hepatitis B surface antigen among subjects vaccinated with hepatitis B virus and did not detect a difference between responses in healthy subjects and those with MS. Ozakbas et al. [35 ] could not demonstrate differences in human leukocyte antigen haplotypes between immunized and nonimmunized MS patients. The sample size of this study was small (n ¼ 11 immunized, 71 nonimmunized MS patients, 20 healthy volunteers) and the method of selection and allocation was not fully transparent. The general approach, however, aiming to achieve immunological insight into the pathophysiology of MS and its relation to infection (e.g. cross reactive antibodies with neuronal tissues) might be worth pursuing.
Guillain-Barré syndrome
Thirty years ago, an increased frequency of Guillain-Barré syndrome (GBS) was observed following a swine influenza vaccine [36] . Different influenza vaccines have been used ever since, and no increased risk of GBS could be associated with any of them. One study during the 1992-94 seasons, however, demonstrated a relative risk of 1.7 (CI 1.0-2.8; P ¼ 0.04) within 6 weeks following immunization and a peak at 2 weeks, suggesting a potentially increased risks of less than one additional case of GBS per 1 million persons vaccinated [37] . Ever since then the reporting rate of GBS had remained stable while the number of doses administered has increased disproportionately, rendering a causal relation in a defined subpopulation unlikely.
During introduction of the tetravalent conjugated meningococcal vaccine (MCV4) in the US, several cases of GBS were identified to be temporally associated with immunization by the national passive surveillance system. Fifteen cases of GBS within 6 weeks of immunization related to a reporting rate of 0.2 per 100 000 personmonths. The corresponding background rate of GBS derived from two large linked healthcare databases was 0.1 per 100 000. The reporting rate ratio for GBS following MCV4 was 1.77 (95% CI 0.96-3.07). Hence there appears to be no significant increased risk of GBS following MCV4 [38 ] .
A recent study in the United Kingdom involving 228 cases of GBS of which seven cases (3%) presented within 42 days following immunization could not demonstrate an increased risk of GBS following any immunization with a relative risk of 1.03 (95% CI 0.48-2.18) [39 ].
Macrophagic myofasciitis
During a hepatitis B vaccine campaign in France the presence of aluminum deposits after vaccination was noted in patients biopsied at the site of injection for suspected systemic inflammatory muscular disease [40] . The entity was termed macrophagic myofasciitis and a causal relation with the vaccine was hypothesized. While this study described a focal histological phenomenon, there is no evidence for macrophagic myofasciitis to be a specific systemic disease [41] . It remains to be elucidated why aluminum salts persists in a small number of vacinees and whether there is an association between the focal microscopic finding and otherwise unspecific generalized weakness. Now that infant immunization schedules increasingly include hepatitis B vaccine immunization, reports in this population increase [42] . Case reports, however, are not helpful to go beyond the stage of speculation. Hence, there remains a lack of evidence for an inappropriate immune reaction and for a causal relation to immunization.
Extensive limb swelling
Swelling at the injection site extending to the adjacent joints was observed following acellular pertussis vaccine, particularly after the fourth and fifth doses. A dose dependency could be shown in a large trial including 20 000 subjects aged 15-27 months receiving nine different formulations [43 ] .
Sensitization by Langerhans cells and subcutaneous injection was also hypothesized. A reduction of local reactions by using a longer (25 mm) needle was observed in a recent study of 696 children receiving diphtheriatetanus-whole cell pertussis, Haemophilus influenzae type b and a serogroup C meningococcal conjugate vaccine [44 ] . It would be interesting to determine whether a correlation with needle size can be observed for extensive limb swelling, as the main site of the reaction appears to be the subcutaneous tissue [45 ,46 ] .
Anaphylaxis
Anaphylaxis is a rare but well recognized AEFI with allergic sensitization occurring to a given vaccine's immunogens or excipients (e.g., preservatives, antibiotics and adjuvants). The incidence of anaphylaxis following any vaccine is estimated to be less than one case per 1 million doses [47-49].
There is no evidence that egg allergy and MMR vaccine are associated. Viruses are not cultivated on eggs but chick embryo cell cultures. Hence, egg allergy does not prevent or warrant delayed immunization. Because anaphylaxis is exquisitely rare in children with known allergic predisposition, more often occurs in children not allergic to eggs, there is no reliable predictor of anaphylaxis as an AEFI, community-based MMR immunization has repeatedly been shown to be safe, and every physician should be able to respond to allergic reactions to any administered substances including vaccines, community based immunization of children with egg allergy is widely recommended and increasingly encouraged [50, 51] . It is hypothesized, however, that allergic predispositions to any of the excipients including gelatin or neomycin may be involved in the development of anaphylaxis as an AEFI [48, 52 ] .
Oculo-respiratory syndrome
Oculo-respiratory syndrome (ORS) was first reported in Canada in 2000 and is a clinical entity consisting of various combinations of red eyes, facial swelling, respiratory symptoms and fever [53] . The initial reporting rate was about 10 per 100 000 doses of influenza vaccine. Particularly affected was the age group 40-60 years, females, first time recipients, and those with an allergic predisposition [54] . Recurrence of ORS following revaccination was observed. Symptoms were generally milder, however, despite their increased number [55] [56] [57] [58] .
ORS was primarily associated with a single manufacturer's inactivated trivalent split-virus influenza vaccine. Electron microscopy found a disproportionate number of virion aggregates in the Canadian vaccine used during the 2000-2001 season [59] . A change in the manufacturing process resulted in a reduced number of large virion aggregates. A reduction of reports to one per 100 000 doses was observed [53] . Incidence rates were then similar to other inactivated influenza vaccines [54, 56] . In a prospective study including 690 immunized infants and toddlers and their household contacts, no difference between immunized and nonimmunized household members was observed regarding symptoms of ORS [60 ] .
In retrospect, it appears that ORS might not be a new AEFI specific to a single vaccine, but was detected as a passive surveillance signal during the 2000/2001 season, subsequently augmented by increased reporting [61] .
With the aim to differentiate rather mild and unspecific symptoms, occurring frequently in exposed and unexposed individuals during the winter season, from those rare cases requiring medical attention to the degree that influenza might elicit, a more stringent case definition might be useful to guide further investigations at this stage.
Bell's palsy
An increased risk of Bell's palsy was observed following a novel nasal influenza vaccine during the 2003/2004 season in Switzerland with an OR of 84.0 (95% CI 20-352), a relative risk almost 20 times that of controls and 13 excess cases per 10 000 vaccinees [62] . It was hypothesized that the adjuvant, a heat-labile enterotoxin of Escherichia coli, could have been the causal agent. As a consequence the vaccine was withdrawn. Concern about an increased risk of Bell's palsy following different influenza vaccines was then raised by passive reporting data from the United States and the United Kingdom [63 ,64] . A recent self-controlled case-series using a large linked database in the United Kingdom, however, rejected the hypothesis for both parenteral influenza and pneumococcal vaccines with a relative incidence estimate of 0.92 (95% CI 0.78-1.08) [63 ] .
Immune overload
The notion that immunization poses a burden to the immune system in early life is still a widespread belief [65 ,66 ,67,68] . The most prevalent aspects of this variably interpreted term are discussed here.
First, the capacity to respond to simultaneous stimuli depends on the general 'fitness' of the immune system. The immune system of a healthy vaccinee has the estimated capacity to react to over 10 9 antigens simultaneously [69] . The number of antigens presented to an individual in the frame of immunization is 6-8 logs less. Infants are estimated to be able to cope with 10 000 theoretical vaccines of 100 antigens with 10 epitopes each [68] . Children with febrile illness at the time of immunization have been shown to mount immune responses similar to healthy individuals, indicating that reaction to administered antigens does not limit the immune systems reactions. Data on the reactogenicity of immunizations in patients with acquired immune deficiency, however, are limited. In view of the globally increasing burden of HIV, optimal prelicensure and enhanced postlicensure surveillance are necessary.
Second, there is insufficient evidence supporting the concern that vaccines would weaken or otherwise harm the immune system. Immunogenicity of combination vaccines generally is not inferior to separate administration [70,71 ,72 ,73,74 ] . Some studies even observed a cross-protective effect against infectious diseases not targeted by a given vaccine and hypothesized that the simultaneous presentation of multiple antigens might unspecifically stimulate the immune system resulting in increased 'immunological fitness' rather than compromising it [75] . There is a need for optimized communication of these findings by healthcare providers [65 ,66 ] .
Intussusception
The first oral rotavirus vaccine, previously licensed in the US (Rotashield; Wyeth, Marietta, Pennsylvania, USA), was a tetravalent rhesus-human reassortant rotavirus vaccine, highly effective in preventing severe rotavirus gastroenteritis. Nine months after licensure, however, the vaccine was withdrawn due to concerns about an increased risk of intussusception [76, 77 ] . In subsequent clinical trials, it was estimated to be between one in 10 000 and one in 30 000 vaccine recipients in industrialized countries. The withdrawal of Rotashield in the USA had a global effect and remains an issue of controversy in view of the global burden of rotavirus disease: since the date of withdrawal several million children's lives could have been saved, if the vaccine was still available, particularly in developing countries where mortality is high. The Rotashield incident has emphasized the value for postlicensure surveillance of the highest standards available and highlighted the challenges of weighing risks and benefits of a vaccine for a given population with a global perspective in mind.
Two novel rotavirus vaccines were recently developed. A pentavalent human-bovine reassortant vaccine (WC3 strain) and a monovalent human rotavirus vaccine (HRV).
Both were shown to be safe in prelicensure studies specifically designed for optimized safety monitoring and including a unprecedented sample size of over 60 000 infants [78 ,79 ] . The relative risk of intussusception was 1.6 (95%CI 0.4-6.4) for WC3 and 0.85 (95%CI 0.3-2.4) for HRV. Both vaccines have been tested in the target age groups and in healthy individuals. Intussusception, however, may occur later in life and safety in immunocompromized patients has not been shown yet. Thus, in countries introducing these vaccines, enhanced postlicensure surveillance is being implemented to optimize detection of potential rare AEFI including intussusception as well as the effects of vaccine virus shedding. A globally coordinated safety assessment with standardized methodology (including a uniform case definition for intusssusception [80] ) will be key for successful monitoring. Safety and efficacy studies of oral rotavirus vaccines in HIV positive infants are underway.
Sudden unexpected death
An association of sudden infant death syndrome (SIDS) has been alleged and rejected following several vaccines. On the contrary, a decreased risk was shown and hypothesized to be due to the protection from infectious diseases in early life [81] [82] [83] [84] [85] [86] .
Five reports of SIDS accumulated after licensure of hexavalent vaccines by the European Medicines Agency (EMEA). This led to analysis of immunization as a risk factor in an ongoing case-controlled study of SIDS in Germany [87 ] . In this study, 129 SIDS victims were included during the first 2 years after licensure of two hexavalent vaccines. Twenty cases and 100 controls received hexavalent vaccines. Mulivariate analysis resulted in an OR of 0.77 (95%CI 0.26-2.24). Two infants (five infants if adjusted for underreporting) died within 2 days after immunization. The expected number of deaths (i.e., number of SIDS expected within 2 days of any day of the year), however, was two resulting in a standard mortality rate (SMR) of 2.38 (95% CI 0.77-5.55). Thus, the number of deaths was within the 95% CI.
Passive surveillance data 3 years following introduction of the vaccine in Germany, also showed that SMRs did not exceed expected rates in the first year of life. The SMR for sudden unexpected death (SUD) within 1 day and 2 days following one vaccine administered in the second year of life were 31.3 (95% CI 3.8-113.1; two cases observed; 0.06 cases expected) and 23.5 (95% CI 4.8-68.6; three cases observed; 0.13 cases expected). This was considered a true signal and intensified surveillance for SUD was recommended [88] . Further scientific discussions related to the methodological challenges of case ascertainment and study design reflect the complexity of monitoring and evaluating associations between ill defined syndromes of unknown cause and pathophysiology and immunization.
Thrombocytopenia
Thrombocytopenia (platelet count below 150 Â 10 9 /l) is observed following several wild-type virus infections and some immunizations. The pathophysiology, however, remains to be elucidated. In an early elegant trial with live measles vaccine, an asymptomatic decrease of the platelet counts of more than 25 Â 10 9 /l was observed in 86% of vaccinees. The decrease was observed after several reexposures, indicating a causal relation. Clinical manifestation of thrombocytopenia after immunization, however, is rare. It appears to be most frequent following MMR vaccine with an estimated hospitalization rate of three per 100 000 immunized children [89, 90 ] . Clinical presentation resembles acute idiopathic thrombocytopenia (ITP) of childhood, which in itself is an ill-defined condition [91 ] . The use of the term ITP appears to be a misnomer in the context of AEFI assessment. The observed event is thrombocytopenia, with or without clinical manifestation. The cause of an idiopathic event is unknown. Hence, exploring ITP as an AEFI invokes petitio principii: a logical fallacy in which the proposition to be proven is assumed implicitly or explicitly in one of the premises.
Squalene
Squalene is an oil produced by plants, animals and in the human skin. For over 10 years, it has also been licensed as part of an adjuvant (MF59) in commercially available influenza vaccines and various vaccines in development, including prepandemic influenza vaccines. Millions of doses have been administered and there was no signal in any surveillance system. Yet, health problems of Gulf War veterans have been claimed to be related to antisqualene antibodies as a consequence of exposure to immunization against anthrax [92] . The initial allegations were refuted, however, based on methodological deficiencies of the study, the presence of such antibodies independently of immunization status, and the absence of squalene administration to veterans [93] . More recently a controlled study on subunit influenza vaccine demonstrated that antibody responses against squalene were neither induced nor boosted by vaccination [94 ] .
Immunization safety organizations
Vaccine safety concerns generally follow a pattern of sudden onset, rapid progression and prolonged recovery. The beginning is often a case series (i.e. a number of exposed subjects with a common outcome), which is followed by broadcasting of the finding through multiple channels. It is then the task of scientific investigations to gradually increase the evidence base to confirm or reject the hypothesis. Generating high quality information at times where opinions are prevailing can be challenging.
Recommended resources aiming to provide information based on the highest scientific standards are listed in Table 3 .
The Brighton Collaboration (website: www.brightoncolloaboration.org) is establishing globally standardized case definitions for AEFIs and guidelines for collection, analysis and presentation of vaccine safety data. This will advance immunization safety by facilitating comparison of adverse events across trials and surveillance systems. An up-to-date list of available case definitions and guidelines is posted on the collaboration's website as they become available. The use of Brighton Collaboration definitions is also increasingly recommended by national and international organizations including the WHO, Food and Drug Administration (FDA), European Medicines Agency (EMEA), Council for International Organizations of Medical Sciences (CIOMS), and the American Academy of Paediatrics (AAP).
Conclusion
Several new vaccines have recently been licensed and introduced in national immunization programs (e.g., rotavirus, influenza, human papilloma virus, pneumococcal, meningococcal, and hexavalent vaccines). While high quality epidemiological data are suggestive for or against safety concerns, discussions around the methodological quality of such data are needed to weigh statistical significance. Strategies to promote the preferential implementation of laboratory studies including immunological and genetic testing to explore potential pathophysiological mechanisms as early as possible in the course of investigating a safety signal would be useful to develop. Such studies would also allow sub-analyses of affected patients aiming to identify confounders in epidemiological studies. While it is comforting to know that most children will not experience adverse events following immunizations, some do and we might learn from analyzing such cases more closely rather then disregarding them entirely as part of statistical background noise. It is the study of these subgroups that will provide further insight into specific and nonspecific reactions to immunological stimuli in terms of safety and immunogenicity. Safety data of recently licensed and more widely recommended vaccines indicate that the observed AEFI are mild and transient and do not outweigh their protective benefits.
The association of Bell's palsy and ORS with influenza vaccines have raised concern about the challenging regu-latory control of vaccines. This is particularly so for vaccines, which are evaluated annually for modification and potentially redesigned to optimize protection for the expected circulating strains. Optimizing prelicensure safety assessment and enhancing postlicensure surveillance of influenza vaccines will be paramount for continued public confidence, particularly in view of outbreak control of endemic or pandemic strains.
The scientific framework to detect and investigate vaccine safety concerns, however, is increasingly robust and the risk-benefit ratio for the individual and the community is much in favor of widespread use of currently licensed vaccines.
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